News Themis Medicare Limited NSE India S.E.

Equities

THEMISMED

INE083B01024

Market Closed - NSE India S.E. Other stock markets 07:43:54 2024-05-24 am EDT			5-day change	1st Jan Change
213.2 ^INR	+0.12%		+1.38%	-0.21%

May. 14	Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024	CI
Feb. 10	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024	May. 14	CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
Themis Medicare Limited Launches REMITHEM	Nov. 10	CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Split: 10 of 1	23-10-09	FA
Split: 10 of 1	23-10-09	FA
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary	23-09-20	CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director	23-09-09	CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023	23-09-07	CI
Ex-dividend day for final dividend	23-08-31	FA
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-13	CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-13	CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023	23-05-13	CI
Themis Medicare Limited Announces Board Resignations	23-05-02	CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection	23-02-17	MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing	23-02-17	CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-03	CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India	23-01-03	MT
Themis Medicare Ltd. Launches Lenzetto Â¡Global Brand of Estradiol Novel Drug Delivery System	23-01-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Themis Medicare Limited NSE India S.E.

Equities

THEMISMED

INE083B01024

Summary

Filters